Product Description
Mechanisms of Action: p53 Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ECOG-ACRIN Cancer Research Group
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Colorectal Cancer|Liver Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| The PUMP Trial | P3 |
Recruiting |
Liver Cancer|Colorectal Cancer |
2029-06-30 |
2024-11-27 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/08/2024 |
PubMed |
Fluoropyrimidines trigger decay of hypomodified tRNA in yeast. |
|
03/28/2024 |
PubMed |
High OXPHOS efficiency in RA-FUdr-differentiated SH-SY5Y cells: involvement of cAMP signalling and respiratory supercomplexes. |
|
03/22/2024 |
PubMed |
Tryptophan residues in TDP-43 and SOD1 modulate the cross-seeding and toxicity of SOD1. |
|
01/19/2023 |
News Article |
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway |